KR20220071225A - 노틴-면역자극제 접합체 및 관련 조성물 및 방법 - Google Patents
노틴-면역자극제 접합체 및 관련 조성물 및 방법 Download PDFInfo
- Publication number
- KR20220071225A KR20220071225A KR1020227013406A KR20227013406A KR20220071225A KR 20220071225 A KR20220071225 A KR 20220071225A KR 1020227013406 A KR1020227013406 A KR 1020227013406A KR 20227013406 A KR20227013406 A KR 20227013406A KR 20220071225 A KR20220071225 A KR 20220071225A
- Authority
- KR
- South Korea
- Prior art keywords
- conjugate
- peptide
- notine
- cys
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908305P | 2019-09-30 | 2019-09-30 | |
| US62/908,305 | 2019-09-30 | ||
| PCT/US2020/053258 WO2021067261A1 (en) | 2019-09-30 | 2020-09-29 | Knottin-immunostimulant conjugates and related compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220071225A true KR20220071225A (ko) | 2022-05-31 |
Family
ID=75337493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227013406A Pending KR20220071225A (ko) | 2019-09-30 | 2020-09-29 | 노틴-면역자극제 접합체 및 관련 조성물 및 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220257785A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4037709A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022549915A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220071225A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114585382A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020357806A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156165A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021067261A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| CA3303472A1 (en) | 2018-04-13 | 2026-05-13 | Massachusetts Institute Of Technology | Brush prodrugs and uses thereof |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| AU2020277470A1 (en) * | 2019-05-22 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Drug conjugates and methods of using same |
| CA3154334A1 (en) * | 2019-10-16 | 2021-04-22 | Jeremiah A. Johnson | Brush prodrugs and uses thereof |
| AU2024379520A1 (en) * | 2023-11-16 | 2026-06-11 | Changping National Laboratory | N-oxide immune agonists activation by radiotherapy |
| WO2025193946A2 (en) * | 2024-03-14 | 2025-09-18 | Genentech, Inc. | Peptides binding lrrc15 and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2817197C (en) * | 2010-11-08 | 2020-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| US9587001B2 (en) * | 2012-10-19 | 2017-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
| WO2014201245A1 (en) * | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
| EP3180018B1 (en) * | 2014-08-12 | 2019-07-24 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein |
| WO2017139570A1 (en) * | 2016-02-12 | 2017-08-17 | Massachusetts Intitute Of Technology | Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne |
| US10765625B2 (en) * | 2016-03-15 | 2020-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Knottin-drug conjugates and methods of using the same |
| BR112019021520A2 (pt) * | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| AU2020277470A1 (en) * | 2019-05-22 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Drug conjugates and methods of using same |
| US20230211001A1 (en) * | 2020-07-30 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Lysosomal Targeting Molecules Comprising Knottin Peptides And Related Compositions And Methods |
-
2020
- 2020-09-29 CA CA3156165A patent/CA3156165A1/en active Pending
- 2020-09-29 KR KR1020227013406A patent/KR20220071225A/ko active Pending
- 2020-09-29 AU AU2020357806A patent/AU2020357806A1/en active Pending
- 2020-09-29 US US17/762,694 patent/US20220257785A1/en active Pending
- 2020-09-29 CN CN202080072773.4A patent/CN114585382A/zh active Pending
- 2020-09-29 EP EP20870659.8A patent/EP4037709A4/en active Pending
- 2020-09-29 WO PCT/US2020/053258 patent/WO2021067261A1/en not_active Ceased
- 2020-09-29 JP JP2022519458A patent/JP2022549915A/ja active Pending
-
2025
- 2025-08-21 JP JP2025138126A patent/JP2026004279A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4037709A4 (en) | 2023-10-11 |
| JP2026004279A (ja) | 2026-01-14 |
| CN114585382A (zh) | 2022-06-03 |
| US20220257785A1 (en) | 2022-08-18 |
| WO2021067261A1 (en) | 2021-04-08 |
| JP2022549915A (ja) | 2022-11-29 |
| CA3156165A1 (en) | 2021-04-08 |
| AU2020357806A1 (en) | 2022-05-26 |
| EP4037709A1 (en) | 2022-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220257785A1 (en) | Knottin-immunostimulant conjugates and related compositions and methods | |
| US20240309058A1 (en) | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof | |
| US12492224B2 (en) | Bicyclic peptide ligands specific for PD-L1 | |
| US10765625B2 (en) | Knottin-drug conjugates and methods of using the same | |
| KR102057356B1 (ko) | Xten 콘주게이트 조성물 및 그의 제조 방법 | |
| US20250326866A1 (en) | Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof | |
| Eder et al. | Bicyclic peptides as a new modality for imaging and targeting of proteins overexpressed by tumors | |
| US12551567B2 (en) | Bicyclic peptide ligands specific for PD-L1 | |
| KR101216008B1 (ko) | 바이포달 펩타이드 바인더 | |
| KR20170073611A (ko) | Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드 | |
| CN101558081A (zh) | 用于诊断和治疗应用的纤维蛋白结合肽缀合体 | |
| Mishra et al. | Cell-penetrating peptides and peptide nucleic acid-coupled MRI contrast agents: evaluation of cellular delivery and target binding | |
| AU2005328644A1 (en) | Methods for preparing multivalent constructs for therapeutic and diagnostic applications | |
| EP3197920A1 (en) | Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages | |
| WO2011071279A2 (ko) | Bpb-기반 카르고 운반 시스템 | |
| KR20220012278A (ko) | 약물 컨쥬게이트 및 이의 사용 방법 | |
| CN103038248B (zh) | Rhamm结合肽 | |
| KR102166549B1 (ko) | 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트 | |
| Cordova et al. | Aminopeptidase P mediated targeting for breast tissue specific conjugate delivery | |
| JP2026501108A (ja) | ソルチリンの標的化 | |
| US20030113819A1 (en) | Carrier peptide and method for delivery of molecules into cells | |
| EP1866332B1 (en) | Use of Crotamine and Composition | |
| US20200390898A1 (en) | Knottin-drug conjugates and methods of using the same | |
| Bánóczi et al. | Amino acid and peptide bioconjugates | |
| Novak et al. | N-terminal cysteine as minimalistic handle for dual, site-selective bioconjugation: application to an anti-HER2 affibody reveals synergy of two conjugated drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |